The company applies antibody technologies to create breakthrough therapeutics, targeting interleukin-11 (IL-11), a cytokine that plays a central role in fibrosis and tumor microenvironment organization. Their lead candidate, LASN01, is a monoclonal antibody that blocks IL-11 receptor alpha, potentially offering superior efficacy compared to other factors like TGF-β and CTGF. Lassen Therapeutics' pipeline focuses on fibrosis, rare diseases, and oncology, providing healthcare professionals with access to innovative treatments.